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ABSTRACT 18 
 In a genome-wide siRNA screen, we recently identified the interferon (IFN) 19 
inducible protein 35 (IFI35, also known as IFP35) as a factor required for VSV infection. 20 
Studies reported here were conducted to further understand the role and requirement of 21 
IFI35 in VSV infection. Consistent with the siRNA screening data, we found that 22 
depletion of IFI35 led to reduced VSV replication at the level of viral gene expression. 23 
Although no direct interaction of IFI35 with the viral replication machinery was observed, 24 
we found that IFI35 negatively regulated the host innate immune response and rescued 25 
poly(I:C)-induced inhibition of VSV replication. Promoter-driven reporter gene assays 26 
demonstrated that IFI35 overexpression suppressed the activation of IFNβ and ISG56 27 
promoters, whereas its depletion had opposite effect. Further investigation revealed that 28 
IFI35 specifically interacted with RIG-I and negatively regulated its activation through 29 
mechanisms that include: (i) suppression of dephosphorylation (activation) of RIG-I and 30 
(ii) proteasome-mediated degradation of RIG-I via K48-linked ubiquitination. Overall, the 31 
results presented here suggest a novel role for IFI35 in negative regulation of RIG-I 32 
mediated antiviral signaling, which will have implications for diseases associated with 33 
excessive immune signaling.  34 
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IMPORTANCE  35 
Mammalian cells employ a variety of mechanisms including production of 36 
interferons (IFNs) to counteract invading pathogens. In this study, we identified a novel 37 
role for a cellular protein, the IFN inducible protein 35 (IFP35/IFI35), in negatively 38 
regulating the host IFN response during vesicular stomatitis virus (VSV) infection. 39 
Specifically, we found that IFI35 inhibited activation of the RNA sensor, the retinoic acid 40 
inducible gene I (RIG-I), leading to inhibition of IFN production and thus resulting in 41 
better replication of VSV. The identification of a cellular factor that attenuates IFN 42 
response will have implications towards understanding of inflammatory diseases in 43 
humans such as Systemic Lupus Erythromatosus and Psoriasis that have been found to 44 
be associated with defects in the regulation of host IFN production.  45 
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INTRODUCTION 46 
 Negative strand RNA viruses employ diverse strategies to counter the host 47 
innate immune response (1). Vesicular stomatitis virus (VSV), a prototypic member of 48 
the Rhabdoviridae family with a non-segmented negative-strand RNA genome, 49 
replicates exclusively in the cytoplasm of the host cells. Among the five proteins 50 
encoded by VSV, the nucleocapsid protein (N) and the matrix protein (M) are crucial to 51 
evade as well as impair cellular antiviral responses (2). VSV N protein binds to newly 52 
synthesized viral genomic RNA during replication, which prevents the formation of 53 
dsRNA intermediates and thereby helps avoid the recognition by the viral RNA sensors 54 
to mount innate immune responses (1). On the other hand, VSV M causes a global 55 
inhibition of host gene expression by abrogating the nucleo-cytoplasmic export of host 56 
mRNAs (3-6). This leads to down-regulation of the overall antiviral response during VSV 57 
infection. Although VSV is highly efficient in invading a wide range of cell types, its 58 
growth is attenuated in cells with a pre-existing antiviral state (1). This suggests that 59 
VSV lacks inherent mechanism(s) to counteract an active innate immune response 60 
immediately after entry into the cells. In this context, VSV may need to depend on host 61 
cell factors to counter the antiviral response to allow efficient replication. 62 
 Our recent genome-wide screen for host factors identified the interferon inducible 63 
gene IFI35 (also known as IFP35) as a factor required for VSV infection (7). It was 64 
intriguing to find the requirement for an interferon stimulated gene (ISG) in virus 65 
infection, since majority of ISGs are known to exert antiviral functions to facilitate 66 
clearance of virus infection. IFI35 is a 35 kDa protein first identified by screening cDNA 67 
libraries of HeLa cells stimulated with IFN-γ (8). It contains an atypical leucine zipper 68 
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domain that lacks the basic region essential for DNA binding but can homo- and hetero-69 
dimerize with its binding partners through the N-myc interacting domains (NIDs) (9, 10). 70 
It also interacts with another ISG called N-myc interacting protein (Nmi) to form a 200-71 
400 kDa high molecular mass complex (HMMC) in response to IFN-α treatment (10). 72 
The interaction of IFI35 with Nmi prevents IFI35 from proteasomal degradation (11). 73 
However, the functional consequence of the HMMC formation and/or the proteasomal 74 
degradation of IFI35 in the context of antiviral signaling are not yet understood.  75 
In contrast to the classical role of ISGs in antagonizing virus infections, several 76 
ISGs are known to play regulatory functions to control excessive antiviral signaling. 77 
Recently, ISGs such as ISG56, Optineurin, gC1qR, LGP2 and SARM have been shown 78 
to negatively regulate the antiviral response by interfering with interactions between 79 
signaling components (12-16) whereas another group of ISGs including ISG15, A20, 80 
RNF125, TRIAD3a, PCBP2 and Ro52 induce degradation of signaling factors via the 81 
ubiquitin-proteasome system (17-22). Importantly, the physiological relevance of 82 
negative regulators is highlighted by the fact that many inflammatory diseases in 83 
humans such as Systemic Lupus Erythromatosus and Psoriasis have been found to be 84 
associated with defects in the regulation of host IFN production  (23). The observations 85 
that IFI35, an ISG, is required for VSV infection and that it does not interact directly with 86 
any of the viral components led us to consider the possibility that IFI35 may support 87 
VSV infection by functioning as a negative regulator of innate antiviral response in 88 
infected cells. 89 
 RIG-I is a well-known pathogen recognition receptor (PRR) for negative 90 
stranded viruses such as VSV, Sendai virus, Influenza and some positive-stranded 91 
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viruses like hepatitis C and dengue virus (24). RIG-I recognizes short dsRNA and 92 
ssRNA with 5 triphosphate ends through a conserved DExD/H RNA helicase domain. 93 
The RNA helicase domain is essential for viral RNA recognition and activation whereas 94 
the CARD domains are essential for downstream signaling (25). Many recent studies 95 
have focused on understanding of the regulatory mechanisms of RIG-I activation 96 
mediated through post-translational modifications such as phosphorylation and 97 
ubiquitination (26, 27), This is particularly important since activation of PRRs, in general, 98 
is crucial to prevent excessive signaling during virus infection and also after the infection 99 
is cleared. Studies have shown that dephosphorylation (of Ser8 and Thr170 residues) of 100 
RIG-I by the phosphatases PP1α/γ (28) and subsequent K63-linked ubiquitination are 101 
two major modifications that promote RIG-I activation (29-31). On the other hand, K48-102 
linked ubiquitination and ISG15 conjugation (ISGylation) are the prominent mechanisms 103 
to down-regulate RIG-I activation (17, 19, 28). Thus, the array of regulatory 104 
mechanisms employed by the host cells underscore the importance of fine tuning of the 105 
PRR response during virus infection. 106 
 In this report, we have investigated the supportive role of IFI35 in VSV infection. 107 
Our studies reveal that IFI35 functions as a negative regulator of the host antiviral 108 
response. Specifically, we have found that IFI35 negatively regulates the RIG-I 109 
mediated antiviral signaling pathway. Our data suggest that IFI35 suppresses RIG-I 110 
activation and also mediates its proteasomal degradation through ubiquitination. Since 111 
RIG-I is the primary sensor during VSV infection (32), its down-regulation may help the 112 
virus to replicate better. Overall, the key findings of this study uncover a new role for 113 
IFI35 in negatively regulating virus triggered RIG-I antiviral signaling. 114 
7 
 
MATERIALS AND METHODS 115 
Cells and reagents. HeLa and HEK293 cells were obtained from ATCC and 116 
maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and the 117 
antibiotics (PKS): penicillin (100 units/ml), kanamycin (20 units/ml) and streptomycin (20 118 
units/ml). Baby hamster kidney (BHK-21) cells were maintained in MEM supplemented 119 
with 5% FBS and 1X PKS. We generated HEK293 cells stably expressing a 3xFlag 120 
tagged IFI35 (3xF-IFI35) by transfection of cells with a plasmid encoding IFI35 tagged 121 
with 3xFlag sequence at its amino-terminus and continuously passaging the cells in 122 
DMEM supplemented with G418 (1mg/ml). A similar stable cell line (EV cells) 123 
transfected with an empty vector was also generated and used in control experiments. 124 
Following isolation, the stable cells were maintained in complete media containing G418 125 
(250 µg/ml). G418 was purchased from Invitrogen, MG132, poly(I:C) and calyculin A 126 
were purchased from Sigma Aldrich.  127 
Viruses, infection and titration. Sendai virus (SeV, Cantell strain) was obtained from 128 
Charles River Laboratories. Stocks of wt VSV and VSV-eGFP were prepared as 129 
described earlier (33, 34). VSVΔG virus and VSV nucleocapsids (NCs or RNPs) were 130 
prepared as described previously (35). VSV titers were determined by standard plaque 131 
assay on HeLa and BHK-21 cells. SeV infections were performed using 50 132 
haemagglutinin units per ml (HA units/ml) for 16 h. VSV infections were performed at an 133 
MOI of 1 or 0.1 plaque forming unit (PFU) per cell, unless otherwise indicated. 134 
Antibodies. VSV anti-M (23H12) antibody and anti-phospho RIG-I (Ser8) antibody were 135 
generously provided by Dr. D. Lyles (Wake Forest School of Medicine) and Dr. M. U. 136 
Gack (Harvard Medical School), respectively. Anti-ISG56 (rabbit polyclonal) antibody 137 
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has been described before (36). Mouse monoclonal antibody against IFI35 from Santa 138 
Cruz (Sc-100769), which detects a closely migrating doublet of endogenous IFI35 and a 139 
single band in plasmid-transfected cells, was used. IRF-3 (Sc-33641) and actin (Sc-140 
47778) antibodies were from Santa Cruz Biotechnology Inc.; anti-phospho IRF-3 (Ser-141 
396) antibody (# 4947) was from Cell Signaling Technology Inc.; anti-RIG-I (ab-65588) 142 
antibody was from Abcam; anti-HA (mouse Mab, HA.11 clone) antibody from Covance; 143 
anti-Flag (mouse Mab, Clone M2) antibody, HRP-conjugated goat anti-mouse (A4416) 144 
and goat anti-rabbit (A6154) antibodies were from Sigma Aldrich. Alexa-594 conjugated 145 
goat anti-mouse IgG (A11032), Alexa-488 donkey anti-mouse IgG (A21202) and Alexa-146 
594 goat anti-rabbit (A11037) antibodies were from Invitrogen.  147 
Plasmid constructs. The cDNA encoding the full length ORF of IFI35 (Cat # 148 
SC320222) was obtained from Origene and cloned into pcDNA 3.1(+) Neo vector 149 
(Invitrogen) at the KpnI and NotI sites to obtain the plasmid pcDNA-IFI35. An N-terminal 150 
HA-tagged IFI35 (HA-IFI35) was constructed by cloning the IFI35 ORF into a modified 151 
pHyg vector (Clontech). An N-terminal 3xFlag-IFI35 was also constructed by inserting 152 
the IFI35 ORF from the pcDNA-IFI35 into a modified pcDNA-3xFlag Neo vector. All the 153 
constructs were sequence verified and all the primers used are described in Table 1. 154 
5x-NF-κB luciferase (37), IFNβ-luciferase and ISG56-luciferase (38), myc-TBK-1 (39), 155 
pEFBos-RIG-I and pEFBos-N-RIG-I (37) constructs have been described previously. 156 
Myc-MAVS was a kind gift from Dr. L. Zhang (University of Nebraska-Lincoln). N-157 
terminal tagged GFP-IRF-3 plasmid was a generous gift from Dr. M. U. Gack. pRK5-158 
HA-Ubiquitin-K48 (17605) was purchased from Addgene (40). 159 
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siRNA-mediated silencing. For depletion of endogenous IFI35, we used a combination 160 
of two ORF targeting siRNA duplexes from Qiagen (Hs_IFI35_1 # SI00445760 and 161 
Hs_IFI35_2 # SI00445767). Non-targeting (NT) siRNA (Qiagen # 1027281) was used 162 
as negative control. All siRNAs were used at a final concentration of 15nM unless 163 
otherwise indicated. siRNA transfections were performed following the protocol 164 
described previously (7). 165 
Promoter-driven reporter gene assays. HEK293 cells were used for IFI35 knockdown 166 
using siRNAs as mentioned above and 3xFlag-IFI35 stable cells were used in IFI35 167 
overexpression experiments. Both these cells were transfected with 0.5 μg of IFNβ-luc, 168 
NF-κB-luc or ISG56-luc plasmids along with 50 ng of pRL-TK plasmid (transfection 169 
control) for 32 h. Subsequently, cells were infected with 50 HA units of SeV for 16 h 170 
before harvesting. Cell lysates were subjected to luciferase assay using a Dual-171 
Luciferase assay kit (Promega). Luciferase activity was measured using 20/20n 172 
Luminometer (Turner Biosystems). Luciferase activity was expressed as the relative fold 173 
induction (n-fold) over the level of activity in the NT siRNA transfected or stable EV cells 174 
after normalization to the Renilla luciferase activity.  175 
Quantitative real time PCR (qRT-PCR). Total cellular RNA was extracted using Trizol 176 
(Invitrogen) according to the manufacturer’s protocol. First strand cDNA was 177 
synthesized with 2 μg of total RNA using M-MLV reverse transcriptase (Invitrogen) 178 
according to manufacturer’s protocol. Oligo-dT primers were used for synthesis of all 179 
cDNAs except for VSV anti-genome, in which VSV2955R primer was used. All primers 180 
were used at a final concentration of 200 nM. The cDNA was diluted 2 fold and 200 ng 181 
of cDNA was used for each qRT-PCR reaction. In each reaction, iTaq Universal SYBR 182 
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green supermix (Bio-Rad) was used according to the manufacturer’s protocol and 183 
carried out using Step One Plus Real time PCR system (Applied Biosystems) following 184 
the standard protocol provided by the manufacturer. Relative fold changes were 185 
automatically calculated by the Step One Plus Real time PCR system software (Applied 186 
Biosystems) following the ΔΔCT method. All primer sequences are listed in Table 1.  187 
Plasmid transfections and western blotting. Transfection of plasmids was performed 188 
using Lipofectamine 2000 (Invitrogen) as per manufacturer’s instructions. Usually, 4-6 h 189 
after transfection, fresh growth media was added and incubated for 44-48 h. 190 
Transfection of viral RNPs was performed as described above but incubated for 6-8 h or 191 
until eGFP expression is observed by fluorescent microscopy. Western blotting and 192 
quantification of bands were performed as described before (35). Concentrations of 193 
primary antibodies used are as follows unless otherwise indicated: anti-VSV M (1:2000), 194 
actin (1:10,000), ISG56 (1:10,000), IFI35 (1:2000), IRF-3 (1:2000), p-IRF-3 (1:1000), 195 
RIG-I (1:1000), p-RIG-I (1:1000), Flag Mab (1:2000) and HA Mab (1:2000). The 196 
corresponding secondary antibodies were used at 1:2000 to 1:5000 dilutions.  197 
Immunofluorescence (IF) microscopy. Stable EV cells or 3xF-IFI35 cells were 198 
transfected with IRF-3-GFP plasmid and subsequently infected with 50 HA units/ml SeV 199 
for 16 h and fixed with 4% paraformaldehyde. IRF-3 was visualized from the fused GFP 200 
fluorescence whereas 3xFlag-IFI35 was immunostained with anti-Flag Mab (1:600) and 201 
the secondary antibody Alexa-594 goat anti-mouse (1:1000). In other experiments, 202 
HEK293 cells were mock-infected or infected with SeV, fixed and stained with 203 
antibodies for endogenous RIG-I (1:200) and IFI35 (1:200). The secondary antibodies 204 
used were Alexa-594 goat anti-rabbit (1:400) and Alexa-488 donkey anti-mouse (1:400), 205 
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respectively. Nuclei were stained with 10 ng/ml 4’,6-diamidino-2-phenylindole (DAPI) 206 
(Invitrogen). All images were acquired at 60X magnification using an Olympus 207 
FV500/IX81 inverted laser scanning confocal microscope.  208 
Co-immunoprecipitation (co-IP) assay. 6-well plates containing 50-60% confluent 209 
HEK293 cells were used for co-IP experiments. For the interaction studies, cells were 210 
transfected with 1 µg of EV, HA-IFI35 or Flag-RIG-I plasmids for 30 h. Then, one set of 211 
cells was infected with SeV (50HA units/ml) or left uninfected for another 16 h. After 46 212 
h of transfection/infection, cells were lysed in lysis buffer as described before (35). For 213 
ubiquitination experiments, 0.5 µg of Flag-RIG-I and HA-Ubiquitin-K48 plasmids along 214 
with increasing amounts IFI35 plasmid (0.5, 1 and 2 µg) were transfected for 36 h and 215 
then treated with MG132 or its vehicle (DMSO) for another 12 h. Antibodies used for 216 
immunoprecipitation are: anti-Flag Mab (1:125) and anti-HA Mab (1:250). Following 217 
overnight incubation with the antibodies, 4 mg of protein A-Sepharose beads (GE 218 
Healthcare Bioscience AB) washed 3 times in the lysis buffer were added to each 219 
sample and incubated for 6-8 h. Beads with bound immune complexes were thoroughly 220 
washed with lysis buffer, 30-40 µl 2X SDS-polyacrylamide gel electrophoresis (PAGE) 221 
sample preparation buffer was added and the proteins were resolved in 10% SDS-222 
polyacrylamide gel. Subsequently, immunoblotting was carried out as described in the 223 
western blotting section. 224 
Statistical analysis. Statistical significance between groups was determined by two-225 
tailed paired Student’s t test. p < 0.05 was considered statistically significant. 226 
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RESULTS 227 
Depletion of IFI35 inhibits VSV replication   228 
Our recent genome-wide RNAi screen identified IFI35 as a factor required for 229 
VSV infection (7). Since IFI35 is an ISG, it was intriguing to observe its requirement in 230 
the virus infection. To understand the involvement of IFI35 in VSV infection, we initially 231 
reconfirmed the high-throughput screen results using siRNA duplexes targeting the 232 
open reading frame of IFI35 mRNA and examined the levels of IFI35 protein as well as 233 
the extent of virus replication. With increasing amounts of siRNA, we observed 8-10 fold 234 
reduction in the overall levels of IFI35 protein (Fig. 1A). Although IFI35 depletion 235 
appeared to have reached its peak with 5 nM siRNA, use of lower (1 nM or less) 236 
concentrations resulted in IFI35 deletion in a dose-dependent manner (data not shown). 237 
A 4-6 fold reduction in VSV M protein levels (measure of virus replication) was observed 238 
in cells depleted of IFI35 (Fig. 1A). Depletion of IFI35 also reduced VSV progeny 239 
production significantly (Fig. 1B). These data reconfirmed our genome-wide screening 240 
results and suggested that IFI35 is required for VSV replication and growth.    241 
To identify the step(s) of VSV infection cycle where IFI35 might be involved, we 242 
determined the levels of viral M protein expression in cells depleted of IFI35 and 243 
transfected with viral nucleocapsids, infected with VSVΔG virus or infected with VSV 244 
under single-cycle (MOI=3) or multi-cycle (MOI=0.1) infection conditions as described 245 
previously (7, 35), and found  that IFI35 primarily affected virus replication at the levels 246 
of viral gene expression (data not shown). This observation was further confirmed by 247 
examining the level of viral P mRNA (measure of transcription) and viral antigenome 248 
(measure of replication) by quantitative real time PCR. Results showed a 4-5 fold 249 
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reduction in P mRNA (Fig. 1C) and anti-genome (Fig. 1D) in cells depleted of IFI35 as 250 
compared to the levels in NT siRNA-treated control cells. Since the observed reduction 251 
in genome replication could be due to inhibition of transcription, we examined VSV 252 
replication independent of transcription. This was performed by measuring replication of 253 
VSV defective interfering (DI) particle genomes in HEK293 cells (41) constitutively 254 
expressing the replication proteins of the virus (N, PeGFP, and L). We observed that DI 255 
particle RNA replication in the cells depleted of IFI35 was significantly (4-5 fold) reduced 256 
(Fig. 1E). Importantly, the levels of the viral N, PeGFP, and L proteins were not affected 257 
(data not shown), indicating that IFI35 depletion was responsible for the observed 258 
reduction of VSV DI RNA replication. Collectively, these data suggest a role for IFI35 in 259 
VSV infection at the level of viral RNA transcription and replication.  260 
IFI35 rescues VSV infection by negatively regulating the host antiviral response 261 
 Since our results demonstrated that IFI35 depletion led to reduced VSV RNA 262 
transcription and replication, we investigated if IFI35 co-localizes or interacts with the 263 
VSV transcription and replication machinery. We did not observe any co-localization or 264 
specific interaction of IFI35 with the viral replication proteins N, P, and L (data not 265 
shown), suggesting that IFI35 is not directly involved in VSV replication but may be 266 
indirectly involved in modulating host cell pathways required for viral replication. IFI35 is 267 
an ISG and is induced in response to IFNα/γ treatment (8, 10). In contrast to the 268 
classical role of ISGs in combating virus infection, many ISGs are known to regulate the 269 
antiviral response through negative feedback mechanisms (23, 42). We considered the 270 
possibility that IFI35 is a negative regulator of antiviral response and thereby it may 271 
support VSV replication. Thus, we first examined the IFNβ mRNA production in HEK293 272 
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cells stably expressing 3xFlag-tagged IFI35 (3xF-IFI35) by real time PCR. Stable cells 273 
(EV) transfected with an empty vector were used as control. Because VSV is known to 274 
efficiently block host gene expression, we used Sendai virus (SeV) infection, which 275 
more potently activates a similar antiviral pathway as VSV (1). In comparison to EV 276 
cells, we observed 4-fold reduction in IFNβ mRNA levels in the 3xF-IFI35 stable cells 277 
infected with SeV (Fig. 2A). Additionally, we observed that when HEK293 cells were 278 
depleted of IFI35 using siRNAs, IFNβ mRNA levels were increased significantly (Fig. 279 
2B). The effect of IFI35 on IFNβ mRNA production was similar whether SeV infection or 280 
poly(I:C) transfection was used (data not shown). To further investigate if IFI35 affects 281 
the production of ISGs, we examined the levels of endogenous ISG56 in EV or 3xF-282 
IFI35 cells infected with SeV. Our results show that the ISG56 protein levels were 283 
significantly reduced in 3xF-IFI35 cells compared to the EV cells (Fig. 2C). Collectively, 284 
the results suggest that IFI35 down-regulates the host antiviral response. 285 
The observation that depletion of IFI35 potentiated the production of IFNβ and 286 
also resulted in reduced VSV infection prompted us to examine if overexpression of 287 
IFI35 could rescue VSV infection from suppression induced by the host antiviral 288 
response. Indeed, VSV growth was enhanced (~10 fold) in poly(I:C) transfected 3xF-289 
IFI35 stable cells when compared to the EV cells (Fig. 2D). Overall, these results 290 
indicate that IFI35 negatively regulates the host antiviral response and supports efficient 291 
replication of VSV.  292 
IFI35 attenuates IFNβ activation 293 
To further probe into the IFN signaling pathway that is negatively regulated by 294 
IFI35,  we examined the effect of IFI35 depletion and overexpression on the induction of 295 
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various promoters including IFNβ, NF-κB and ISG56, all which are prominently activated 296 
in response to most virus infections (43). First, we tested the effect of IFI35 depletion on 297 
IFNβ promoter induction. To this end, HEK293 cells treated with NT or IFI35 siRNA 298 
were transfected with a plasmid (IFNβ-Luc) encoding firefly luciferase under an IFNβ 299 
promoter. Subsequently, these cells were infected with SeV to induce the IFNβ 300 
promoter. Under these conditions, we observed a 4-fold increase in the luciferase 301 
activity in IFI35 depleted cells compared to control (Fig. 3A). In SeV-infected 3xF-IFI35 302 
stable cells, significant (5-fold) reduction in luciferase activity was observed compared 303 
to Sev-infected EV cells (Fig. 3B). These data suggest that IFI35 down-regulates the 304 
IFNβ promoter induction, providing further support for our earlier observation on 305 
reduced IFNβ mRNA levels (Fig. 2A and 2B). Next, we examined the effect of IFI35 on 306 
induction of NF-κB promoter. We found only a 2-fold increase or decrease in NF-κB 307 
dependent promoter activity when IFI35 was depleted or overexpressed, respectively, in 308 
SeV-infected cells (Fig. 3C and 3D), suggesting that NF-κB pathway may not play a 309 
major role in IFI35-mediated down-regulation of IFNβ activation. Since we observed that 310 
IFI35 overexpression suppressed ISG56 protein induction (Fig. 2C), we then examined 311 
if this suppression was due to down-regulation of ISG56 promoter activity. We found 312 
about 5-fold enhancement in ISG56 promoter induction in cells depleted of IFI35 (Fig. 313 
3E) and a similar reduction (6-fold) in reporter activity was observed in cells 314 
overexpressing IFI35 as compared to the control (EV) cells (Fig. 3F). Taken together, 315 
these results suggest that IFI35 down-regulates IFNβ activation pathway. 316 
 317 
 318 
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IFI35 down-regulates IRF-3 and IRF-7 activation 319 
 Down-regulation of IFNβ induction by IFI35 could occur either by direct 320 
interaction of IFI35 with the promoter elements or by interfering with activation of 321 
upstream signaling molecules. Since IFI35 lacks DNA binding activity (9) and therefore 322 
may not be directly interacting with the promoter elements, we investigated whether 323 
IFI35 suppresses activation of signaling factors such as NF-κB, IRF-3 and IRF-7 that 324 
function upstream of IFNβ production. We focused our investigation on IRF-3 and IRF-7 325 
activation as IFI35 showed relatively lower effect on NF-κB promoter activation (Fig. 3C 326 
and 3D). We first examined if IRF-3 phosphorylation and nuclear translocation, both of 327 
which are hallmarks of IRF-3 activation (44), are affected by IFI35 depletion or 328 
overexpression. Depletion of IFI35 in HEK293 cells infected with SeV resulted in 329 
increased IRF-3 phosphorylation compared to NT siRNA treated cells infected with SeV 330 
(Fig. 4A). Furthermore, IRF-3 phosphorylation was strongly suppressed in 3xF-IFI35 331 
stable cells when infected with SeV (Fig. 4B). As phosphorylation of IRF-3 leads to its 332 
dimerization and nuclear translocation (45), we examined if IFI35 inhibits nuclear 333 
translocation of IRF-3. To this end, HEK293 cells stably expressing 3xF-IFI35 or control 334 
(EV) cells were transfected with a N-terminal GFP tagged IRF-3 construct (GFP-IRF-3). 335 
Infection of EV cells with SeV led to translocation of IRF-3-GFP from the cytoplasm into 336 
the nucleus whereas the nuclear translocation was abolished in 3xF-IFI35 stable cells 337 
(Fig. 4C). These results indicate that IFI35 inhibits the activation of IRF-3, which likely 338 
accounts for the down-regulation of IFNβ promoter induction.  339 
 Since IRF-7 in most cells other than plasmacytoid dendritic cells is induced upon 340 
virus infection and activated through positive feedback from IFN-α/β signaling (46), we 341 
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examined if IFI35 negatively regulates IRF-7 induction in the HEK293 cells used in our 342 
studies here. Our results show that in SeV-infected cells, IRF-7 mRNA levels were up-343 
regulated when IFI35 was depleted (Fig. 4D) and reduced when IFI35 was 344 
overexpressed (Fig. 4E). Taken together, these results suggest that IFI35 negatively 345 
regulates activation of IRF-3 and IRF-7. Thus, the down-regulation of IFNβ promoter is 346 
likely due to the combined effect of suppression IRF-3 and IRF-7 activation. 347 
IFI35 negatively regulates RIG-I pathway activation 348 
 To investigate if IFI35 down-regulates the antiviral signaling pathway upstream of 349 
IRF-3 and IRF-7, we examined the activation of IFNβ promoter by the signaling 350 
components including TBK1, MAVS/IPS-1 and RIG-I, all of which are known to be 351 
activated during VSV or SeV infection (43). In 3xF-IFI35 stable cells, we observed 352 
significant reduction (3-5 fold) in IFNβ promoter activation induced by RIG-I and the 353 
constitutively active form of RIG-I (N-RIG-I). But the activation was not significantly 354 
altered by the downstream signaling molecules, MAVS and TBK1 (Fig. 5A). In 355 
consistent with this data, we also found significant enhancement in IFNβ promoter 356 
activation by RIG-I and N-RIG-I in HEK293 cells depleted of IFI35 (Fig. 5B), whereas no 357 
significant effect was observed with MAVS and TBK1 expression in these cells (Fig. 358 
5B). These data suggest that IFI35 negatively regulates the host antiviral pathway by 359 
exerting its effect at the level of RIG-I. 360 
 To understand how IFI35 regulates the activity of RIG-I, we examined the 361 
phosphorylation status of RIG-I. Dephosphorylation of Ser8 is a necessary prerequisite 362 
step in RIG-I activation process (30). In SeV-infected HEK293 cells depleted of IFI35, 363 
we observed significantly reduced phosphorylated form of RIG-I by using Ser8 364 
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phospho-specific RIG-I antibody (Fig. 5C). The total RIG-I levels were also slightly 365 
increased. In contrast, the level of RIG-I phosphorylation was partially restored in 3xF-366 
IFI35 stable cells infected with SeV and the total RIG-I was also reduced, indicating that 367 
IFI35 overexpression led to suppression of RIG-I activation (Fig. 5D). Since we 368 
observed changes in total RIG-I levels by depletion or overexpression of IFI35, we 369 
examined if IFI35 affected RIG-I induction at the level of transcription. Results showed 370 
that RIG-I mRNA was up-regulated in cells depleted of IFI35 (Fig. 5E), whereas in 3XF-371 
IFI35 stable cells, it was reduced (Fig. 5F). Since RIG-I is an ISG, the reduced levels of 372 
RIG-I mRNA may be due to overall down-regulation of IFNβ activation. These results 373 
indicate that IFI35 down-regulates the activation of RIG-I, leading to overall suppression 374 
of the antiviral response.      375 
IFI35 interacts with and promotes RIG-I degradation via K48-linked ubiquitination  376 
 To further understand the mechanism by which IFI35 negatively regulates RIG-I 377 
activation, we examined if IFI35 and RIG-I co-localize and/or interact in cells. We 378 
observed enhanced co-localization of endogenous IFI35 and RIG-I in SeV-infected cells 379 
compared to mock-infected cells (Fig. 6A). To determine if the observed co-localization 380 
was due to physical interaction between IFI35 and RIG-I, we performed co-IP assay in 381 
HEK293 cells. Cells were co-transfected with plasmids encoding Flag-RIG-I and HA-382 
IFI35, and subsequently were mock-infected or infected with SeV. The cell extracts 383 
were subjected to co-IP with Flag (Fig. 6B, left panel) or HA (Fig. 6B, right panel) 384 
antibody and immunoblotted with HA or Flag antibody, respectively. Results show that 385 
RIG-I and IFI35 interact with each other in transfected cells in presence or absence of 386 
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SeV infection (Fig. 6B). Overall, both the co-localization and interaction studies suggest 387 
that IFI35 specifically interacts with RIG-I. 388 
 Since the negative regulators such as RNF125 and Siglec-G induce proteasomal 389 
degradation of RIG-I (19, 47), we examined if IFI35 promotes degradation of RIG-I. 390 
Indeed, when HEK293 cells were transfected with Flag-RIG-I along with increasing 391 
amounts of IFI35, we observed a dose dependent reduction in the levels of Flag-RIG-I 392 
but this effect was reversed when cells were treated with a proteasome inhibitor MG132 393 
(Fig. 6C). This suggests that IFI35 promotes degradation of RIG-I through the 394 
proteasome machinery. It is well known that proteins degraded through proteasome 395 
pathway are conjugated to ubiquitin chains via lysine48 (K48) linkage (48). Thus, we 396 
examined if IFI35 promotes K48-linked ubiquitination of RIG-I. As shown in Fig. 6D, a 397 
dose dependent increase in K48-linked ubiquitination of RIG-I was observed with 398 
increasing amounts of IFI35. The levels of free HA-Ub-K48 in whole cell lysates 399 
decreased, indicating that the expressed HA-Ub-K48 was being conjugated to RIG-I. 400 
Concomitant reduction of RIG-I levels was observed in the whole cell lysates (Fig. 6D). 401 
Further, we observed reduction in K48-linked ubiquitination of RIG-I when IFI35 was 402 
depleted using siRNAs (Fig. 6E). These data suggest that IFI35 interacts with RIG-I and 403 
negatively regulates its activation by promoting K48-linked ubiquitination and 404 
degradation by proteasome pathway.   405 
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DISCUSSION 406 
In the present study, we have uncovered a new role for IFI35 as a negative 407 
regulator of the host antiviral response during VSV infection. Consistent with our recent 408 
high-throughput genome-wide siRNA screening study (7) revealing a requirement for 409 
IFI35 in VSV infection, we found that depletion of IFI35 led to significant reduction in 410 
VSV replication. Conversely, overexpression of IFI35 could rescue VSV growth from 411 
poly(I:C)-induced antiviral response. The observation that IFI35 did not interact with any 412 
of the viral components suggested that IFI35 likely exerted its effect by influencing 413 
cellular pathways. The results presented here indicate that IFI35 down-regulates the 414 
host antiviral response mediated by RIG-I. IFI35 appears to down-regulate RIG-I activity 415 
by at least two modes: (i) by keeping the RIG-I in its phosphorylated (inactive) form and 416 
(ii) by mediating proteasomal degradation of RIG-I though ubiquitination. Whether the 417 
requirement of IFI35 is specific to VSV infection is not known at this time, although, we 418 
have observed a moderate requirement of IFI35 during lymphocytic choriomeningitis 419 
virus infection (7). 420 
 Current understanding of the role of IFI35 in virus infections is limiting. IFI35 is an 421 
ISG that is induced in response to treatment of cells with IFN-α/γ (8, 10). We have found 422 
that it is also induced by transfection of cells with poly(I:C) or infection with SeV (data 423 
not shown). The only study reported so far suggests that IFI35 interacts with the bovine 424 
foamy virus (BFV) trans-activator protein Tas and that this interaction blocks the ability 425 
of Tas to activate viral gene transcription, resulting in inhibition of BFV replication (49). 426 
So, in this context, IFI35 exhibits an antiviral role and suppresses the virus replication. 427 
Since infection of HeLa or HEK293 cells (which are of nonhematopoietic origin) by 428 
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foamy viruses do not induce type I IFN response (50, 51), it is possible that the negative 429 
regulatory role of IFI35 in innate immune signaling was not observed readily in these 430 
studies. However, our data clearly demonstrates the supportive role of IFI35 in VSV 431 
infection through negative regulation of innate immune signaling. As viruses differ 432 
significantly in their ability to induce or suppress the host innate antiviral responses, 433 
additional studies will be needed to evaluate the role and requirement of IFI35 during 434 
infection with diverse families of viruses. 435 
Although host innate antiviral response is of paramount significance for 436 
controlling viral infections, unregulated or excessive response may be detrimental to the 437 
host. Therefore, identification of host cell factors and understanding the mechanisms 438 
that negatively regulate these processes are critical to prevent damage to the infected 439 
and neighboring uninfected cells. In this regard, the role of ISGs that function as 440 
negative regulators of antiviral signaling is being increasingly appreciated. Previous 441 
studies have shown that several ISGs, such as ISG56, Optineurin, RNF125 and A20 442 
down-regulate the antiviral response through diverse mechanisms (12, 13, 19, 52) that 443 
include interference with interactions between various signaling components (12-16) or 444 
degradation of signaling factors via the ubiquitin-proteasome pathway. Our studies 445 
presented here show that IFI35 negatively regulates RIG-I mediated antiviral pathway 446 
through multiple mechanisms. Previous studies have shown that activation of RIG-I is 447 
controlled through ubiquitination or deubiquitination of the CARD domains (26). K48-448 
linked ubiquitination of RIG-I is primarily promoted by the E3 ubiquitin ligases RNF125 449 
(19) and the recently identified c-Cbl (47), which results in degradation RIG-I through 450 
the proteasome machinery. On the other hand, removal of K63-linked ubiquitin chains is 451 
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mediated by the tumor suppressor CYLD which leads to inactivation of RIG-I (53). The 452 
results presented here show that IFI35 down-regulates the host antiviral response by 453 
promoting proteasomal degradation of RIG-I. IFI35 interacts with RIG-I and promotes its 454 
degradation through the proteasome pathway via K48-linked ubiquitination (Fig. 6). We 455 
did not observe any significant changes in K63-linked ubiquitination of RIG-I under 456 
conditions of IFI35 overexpression (data not shown), suggesting that negative 457 
regulation of RIG-I mediated by IFI35 occurs primarily through K48-linked ubiquitination 458 
and proteasomal degradation and may not involve deubiquitination. At this time, it is not 459 
known whether IFI35 directly mediates the K-48 linked ubiquitination or facilitates the 460 
recruitment of an E3 ubiquitin ligase. Since IFI35 does not contain any typical E3 461 
ubiquitin ligase domains such as HECT, RING or F-box motifs (54), the latter possibility 462 
of recruiting an E3 ubiquitin ligase seems more likely. It will be interesting to examine if 463 
the K48-linked ubiquitination of RIG-I in the IFI35-RIG-I complex is mediated by known 464 
E3 ubiquitin ligases of RIG-I such as RNF125 and c-Cbl or by a yet unidentified E3 465 
ubiquitin ligase (Fig. 7).     466 
Another mechanism of RIG-I inactivation by IFI35 appears to be through 467 
suppressing the dephosphorylation of RIG-I. Previously, it was shown that RIG-I is 468 
maintained in an inactive state by phosphorylation mediated by PKC-α/β (55). Initial 469 
step of RIG-I activation involves dephosphorylation of the CARD domains mediated by 470 
the phosphatases PP1α/γ (28). We observed that IFI35 overexpression led to 471 
enhancement of RIG-I phosphorylation (Fig. 5D), suggesting that IFI35 also regulates 472 
the activation of RIG-I through direct involvement in the phosphorylation event or 473 
through an indirect mechanism. Interestingly, our preliminary bioinformatics analysis 474 
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has uncovered several potential phosphorylation sites on IFI35 which are predicted to 475 
be phosphorylated by the protein kinase C (PKC) family of kinases (data not shown). 476 
Although the role of phosphorylation/dephosphorylation in modulating IFI35 function is 477 
not clear at this time, it is possible that phosphorylation of both IFI35 and RIG-I by a 478 
common family of kinases may represent an intricate mechanism for IFI35-mediated 479 
negative regulation of RIG-I antiviral response. 480 
Recently, it was reported that Nmi negatively regulates the host antiviral signaling 481 
by promoting degradation of IRF-7 (56). Since Nmi is known to interact with IFI35 and 482 
enhance its stability (11), it is possible that both proteins may act in a synergistic or 483 
additive fashion to negatively regulate a common antiviral signaling pathway, albeit 484 
through different targets. Since the formation of a high molecular mass IFI35-Nmi 485 
complex has been shown to be an IFN-α stimulated event (10), it will be interesting to 486 
investigate if the interaction of Nmi and IFI35 plays any role in augmenting the negative 487 
regulatory effects during virus infections.  488 
IFI35 belongs to a group of atypical helix-loop-helix (HLH) proteins such as Id, 489 
which lack the basic DNA binding region and thus function in a dominant negative 490 
fashion to negatively regulate function of other b-HLH group of transcription factors (57, 491 
58). In this study, we have uncovered a novel role of IFI35 in negatively regulating the 492 
host antiviral response by targeting the RIG-I signaling pathway. Mechanistically, we 493 
have demonstrated that IFI35 down-regulates RIG-I activation by promoting its 494 
proteasomal degradation as well as keeping it in its phosphorylated (inactive) form. 495 
Further studies are required to understand the mechanistic details of this process and 496 
also identify other factors involved in the IFI35 mediated negative regulatory loop. In 497 
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conclusion, identification of IFI35 introduces a new player to the existing group of 498 
molecules that regulate RIG-I antiviral signaling pathway and also highlights the 499 
importance of negative regulation of cellular antiviral responses.  500 
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FIGURE LEGENDS 694 
Figure 1. Depletion of IFI35 inhibits VSV replication. (A) HeLa cells were transfected 695 
with 15 nM of NT siRNA or increasing amounts (5, 10 and 15 nM) of a combination of 696 
two different siRNAs targeting IFI35. At 60 h post-transfection, cells were infected with 1 697 
MOI VSV for 4 h. Levels of IFI35 and VSV M were determined by immunoblotting with 698 
specific antibodies. Actin served as the loading control. (B) HeLa cells were transfected 699 
with 15 nM of NT or IFI35 siRNA for 60 h and infected with 0.1 MOI VSV for 18 h. 700 
Supernatant was harvested and virus titer was determined by plaque assay and 701 
expressed as pfu/ml. Average titers for NT and siIFI35 were 3.9x104 and 2.7x105 pfu/ml, 702 
respectively. (C and D) IFI35 depletion inhibits VSV infection at the level of virus 703 
transcription and replication. HeLa cells were transfected with 15 nM of NT or IFI35 704 
targeting siRNA for 60 h. Subsequently, the cells were infected with 0.1 MOI VSV for 12 705 
h. VSV P mRNA (C) and VSV antigenomic RNA (D) levels in IFI35 depleted HeLa cells 706 
was determined by qRT-PCR. Values were normalized to the internal control β-actin 707 
and expressed as relative change over the NT sample, which was set at 100. (E) IFI35 708 
knockdown inhibits VSV DI RNA replication. NPeGFPL stable cells were transfected 709 
with 15 nM NT or IFI35 targeting siRNA for 60 h. Then, the cells were infected with DI 710 
particles for 14 h and the RNA replication products (both genomic and antigenomic) 711 
were quantitated by semiquantitative RT-PCR as described previously (41). IFI35 and 712 
RPL32 (internal control) mRNA levels also were examined. Data presented in B-D 713 
panels are from three independent experiments and error bars represent mean ± SD of 714 
duplicates. *p < 0.05; **p < 0.01. 715 
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Figure 2. IFI35 rescues VSV infection by negatively regulating host antiviral response. 716 
(A-B) IFI35 down-regulates IFNβ mRNA synthesis. EV and 3xF-IFI35 stable cells (A) or 717 
HEK293 cells transfected with NT or IFI35 siRNAs (B) were infected with SeV for 16 h. 718 
Total RNA was isolated and IFNβ mRNA was quantified by qRT-PCR. Values were 719 
normalized to the internal control GAPDH and expressed as relative fold change over 720 
the mock-infected NT or EV samples, which were set at 1. Error bars represent mean ± 721 
SD of duplicate reactions from two independent experiments. ** p < 0.01. (C) IFI35 722 
overexpression suppresses ISG56 induction. EV and 3xF-IFI35 stable cells were 723 
infected with SeV for 16 h. Cell lysates were used for immunoblotting using ISG56, Flag 724 
M2 (detects 3xF-IFI35) and actin antibodies. (D) IFI35 overexpression rescues poly(I:C) 725 
induced suppression of VSV infection. EV and 3xF-IFI35 cells were transfected with 2 726 
µg poly(I:C) for 16 h and infected with 0.1MOI VSV for 18 h. The supernatants were 727 
harvested and virus titers were determined by plaque assay on BHK-21 cells. Virus 728 
titers are expressed as log10 pfu/ml. Error bars represent mean ± SD from three 729 
independent experiments. ** p < 0.01. 730 
Figure 3. IFI35 attenuates IFNβ activation and signaling. (A-B) Effect of IFI35 on IFNβ 731 
promoter activation. (A) HEK293 cells were transfected with 15nM NT or IFI35 targeting 732 
siRNAs for a total of 76 h. After first 24 h, cells were transfected with 500 ng of IFNβ 733 
luciferase reporter plasmid (IFNβ-Luc) along with 50 ng of pRL-TK plasmid and were 734 
incubated for another 36 h. For the final 16 h prior to harvesting, cells were either mock-735 
infected or infected with SeV. Cell lysates were used for dual luciferase assay. (B) EV 736 
and 3xF-IFI35 stable cells were transfected with 500 ng of IFNβ luciferase reporter 737 
plasmid along with 50 ng of pRL-TK plasmid for 32 h. Subsequently, cells were infected 738 
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with SeV for 16 h and cell lysates were used for dual luciferase assay. (C-D) Effect of 739 
IFI35 on NF-κB promoter activation. Experimental conditions are similar to those in 740 
panels A-B except 500 ng of NF-κB luciferase construct (NF-κB-Luc) was transfected in 741 
place of IFNβ-Luc. (E-F) Effect of IFI35 on ISG56 promoter activation. Experimental 742 
conditions are similar to those in panels A-B except 500 ng of ISG56 luciferase 743 
construct (ISG56-Luc) was transfected in place of IFNβ-Luc construct. Values 744 
represented in all the promoter reporter assays are normalized to NT or EV control cells 745 
and expressed as relative fold change over the mock-infected NT or EV samples, which 746 
were set at 1. Error bars represent mean ± SD from three independent experiments. * p 747 
< 0.05; ** p < 0.01. 748 
Figure 4. IFI35 down-regulates activation of IRF-3 and IRF-7. (A-B) IFI35 down-749 
regulates IRF-3 phosphorylation. (A) HEK293 cells were transfected with 15 nM NT or 750 
IFI35 siRNAs for 60 h and infected with SeV for another 16 h. Cell lysates were 751 
analyzed by immunoblotting using the indicated antibodies. (B) EV and 3xF-IFI35 stable 752 
cells were infected with SeV for 16 h and cell lysates were analyzed immunoblotting 753 
using the indicated antibodies. (C) IFI35 overexpression inhibits nuclear translocation of 754 
IRF-3. EV and 3xF-IFI35 stable cells were grown on coverslips and transfected with 1 755 
μg GFP-IRF-3 plasmid for 32 h and then infected with SeV for 16 h. 3xFlag-IFI35 was 756 
immunostained using anti-Flag antibody. Nuclei were stained with DAPI. (D-E) IFI35 757 
down-regulates IRF-7 induction. (D) HEK293 cells transfected with 15 nM of NT or IFI35 758 
siRNAs for 60 h and infected with SeV for another 16 h. Total RNA was isolated and 759 
subjected to qRT-PCR using IRF-7 specific primers. (E) IRF-7 mRNA was quantified as 760 
described in D from EV and 3XF-IFI35 stable cells infected with SeV for 16 h. Values 761 
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were normalized to the internal control GAPDH and expressed as relative fold change 762 
over the mock-infected EV or NT samples, which were set at 1. Error bars represent 763 
mean ± SD of duplicate reactions from two independent experiments. * p < 0.05. 764 
Figure 5. IFI35 negatively regulates RIG-I pathway activation. (A) EV and 3xF-IFI35 765 
stable cells were transfected with the plasmids encoding RIG-I pathways components 766 
(0.5µg each) MAVS, TBK1, RIG-I and N-RIG-I along with 0.25 µg IFNβ-Luc and 0.025 767 
µg pRL-TK plasmid for 48 h. The cells were lysed and used for dual luciferase assays. 768 
(B) HEK293 cells were transfected with 15 nM of NT or IFI35 siRNAs for 24 h and then 769 
transfected with the plasmids as described in A for another 48 h. Cells were lysed and 770 
used for dual luciferase assays. Luciferase values were normalized to the EV or NT 771 
control cells and expressed as relative fold change over the mock-infected EV or NT 772 
samples, which were set at 1. Error bars represent mean ± SD of two independent 773 
experiments performed in duplicates. * p < 0.05; ** p < 0.01; ns; not significant. (C-D) 774 
IFI35 negatively regulates RIG-I activation. (C) HEK293 cells were transfected with 15 775 
nM NT or IFI35 siRNAs for 60 h and infected with SeV for another 16 h. The cells were 776 
treated with 100 nM calyculin A for 30 min before harvesting. Cell lysates were analyzed 777 
by immunoblotting using the indicated antibodies. Actin served as loading control. (D) 778 
EV and 3xF-IFI35 stable cells infected with SeV for 16 h and processed as described in 779 
C. (E-F) Knockdown or overexpression of IFI35 enhances or suppresses RIG-I 780 
transcription, respectively. (E) HEK293 cells were transfected with 15 nM NT or IFI35 781 
siRNAs for 60 h and infected with SeV for another 16 h. Total RNA was isolated and 782 
used for quantification of RIG-I mRNA levels by qRT-PCR. (F) EV or 3xF-IFI35 stable 783 
cells were infected with SeV for 16 h and processed as in E. Values were normalized to 784 
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the internal control GAPDH and expressed as relative fold change over the mock-785 
infected EV or NT samples set at 1.  ** p < 0.01. 786 
Figure 6. IFI35 interacts with and promotes degradation of RIG-I via K48-linked 787 
ubiquitination. (A) SeV infection enhances co-localization of IFI35 and RIG-I. HEK293 788 
cells were grown on coverslips and mock-infected or infected with SeV for 16 h. The 789 
cells were fixed and immunostained with the indicated antibodies. Nuclei were stained 790 
with DAPI and images were collected at 60X magnification. (B) IFI35 interacts with RIG-791 
I in transfected cells. HEK293 cells were transfected with 0.5 μg of the indicated 792 
plasmids for 32 h. One set of cells were mock-infected while the other set was infected 793 
with SeV for another 16 h. Co-IP and immunobloting was performed with the indicated 794 
antibodies. Expression of proteins from the transfected plasmids was analyzed in the 795 
whole cell lysates (WCL) using the indicated antibodies. (C) IFI35 promotes 796 
proteasomal degradation of RIG-I. Sets of HEK293 cells were transfected with 0.5 μg of 797 
Flag-RIG-I along with increasing amounts of IFI35 (0.5 and 1 μg) for 36 h. One set of 798 
cells was treated with 10 μM MG132 and the other set with DMSO for 12 h. Cell lysates 799 
were analyzed by immunoblotting with the indicated antibodies. (D) IFI35 800 
overexpression enhances K48-linked ubiquitination of RIG-I. Sets of HEK293 cells were 801 
transfected with Flag-RIG-I and HA-Ub-K48 constructs (0.5 μg each) along with 802 
increasing amounts of plasmid expressing IFI35 (0.5, 1 and 2 μg) for 36 h. One set of 803 
cells was treated with MG132 (10 μM) for 12 h and subsequently lysed and used for co-804 
IP and immunoblotting with the indicated antibodies. Another set of cells was treated 805 
with DMSO for 12 h and the whole cell lysates were analyzed by immunoblotting with 806 
the indicated antibodies. (E) IFI35 knockdown reduces K48-linked ubiquitination of RIG-807 
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I. Sets of HEK293 cells were transfected with NT siRNA or increasing amounts of IFI35 808 
siRNA (5, 10 and 20 nM) for 24 h. The cells were transfected with Flag-RIG-I and HA-809 
Ubiquitin-K48 constructs (0.5 μg each) for another 36 h. Cells were subsequently 810 
processed as described in D. 811 
Figure 7. A proposed model depicting the role of IFI35 in negative regulation of RIG-I 812 
signaling. For the sake of simplicity, we have only shown the ubiquitin-mediated 813 
degradation pathway. Viruses like VSV and SeV are recognized by RIG-I, which signals 814 
through downstream factors (IRF-3/IRF7) leading to production of type I IFNs (IFN-α/β). 815 
IFN-α/β in turn induce the synthesis of ISGs including IFI35 which interacts with RIG-I 816 
and inhibits its activation by promoting K48-linked ubiquitination and proteasomal 817 
degradation. The identity of the associated E3 ubiquitin ligase is unknown at this time. 818 
The negative feedback loop mediated by IFI35 leads to down-regulation of the host 819 
antiviral response.   820 
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Table 1. Primers used in this study 821 
 822 
Primer name Primer sequence (5’ to 3’) Used for 
IFI35 KpnI-F ATATATGGTACCGCCGCCACCATGTCAGCCCCA
CTGGATG 
Amplification and 
cloning of IFI35 in 
pcDNA vector IFI35 NotI-R ATATATGCGGCCGCCTAGCCTGACTCAGAGGT
G 
 
HAIFI35 KpnI-F ATATATGGTACCGCCGCCACCATGTACCCATAC
GATGTTCCAGATTACGCTTCAGCCCCACTGGAT
GCC 
Amplification and 
cloning of HA tagged 
IFI35 
IFI35 NotI-R ATATATGCGGCCGCCTAGCCTGACTCAGAGGT
G 
 
VSV P-F GTGACGGACGAATGTCTCATAA Amplification of VSV P 
mRNA VSV P-R TTTGACTCTCGCCTGATTGTAC 
VSV 2795-F GTGACGGACGAATGTCTCATAA Amplification of VSV 
antigenomic RNA 
VSV2955-R TGATGAATGGATTGGGATAACA 
Actin-F CAAGTACTCCGTGTGTGGAT Amplification of Actin 
mRNA Actin-R CATACTCCTGCTTGCTGAT 
IFN-β-F ATGACCAACAAGTGTCTCCTCC Amplification of IFN-β 
mRNA IFN--β-R GGAATCCAAGCAAGTTGTAGCTC 
IRF7-F CCCACGCTATACCATCTACCT Amplification of IRF7 
mRNA IRF7-R GATGTCGTCATAGAGGCTGTTG 
RIG-I-F CTGGACCCTACCTACATCCTG Amplification of RIG-I 
mRNA RIG-I-R GGCATCCAAAAAGCCACGG 
GAPDH-F GCAAATTCCATGGCACCGT Amplification of 
GAPDH mRNA GAPDH-R TCGCCCCACTTGATTTTGG 
VSV DI ACGAAGACCACAAAACCAGATAAAAA Amplification of DI 
RNA 
RPL32-F GCCAGATCTTATGCCCCAAC Amplification of 
RPL32 mRNA RPL32-R CGTGCACATGAGCTGCCTAC 
IFI35-F AACAAAAGGAGCACACGATCA Amplification of IFI35 
mRNA IFI35-R CTCCGTTCCTAGTCTTGCCAA 
Underlined sequences indicate the restriction sites 823 







